{"schema_version":"secwatch.filing_event.v1","accession":"0001438533-26-000013","form_type":"8-K","ticker":"TVTX","cik":"0001438533","company_name":"Travere Therapeutics, Inc.","filed_at":"2026-02-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.090639+00:00","generated_at":"2026-05-16T01:42:12.119768+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Travere reports Q4 net income of $2.7M; FILSPARI sales up 108% YoY to $103.3M","bullets":["FILSPARI U.S. net product sales $103.3M in Q4 2025 (+108% YoY); full year $322M (+144%).","Q4 GAAP net income $2.7M ($0.03/share) vs net loss $60.3M in Q4 2024; non-GAAP net income $33.3M.","PDUFA target for FILSPARI in FSGS is April 13, 2026; commercial launch preparations ongoing.","Cash & securities $322.8M at Dec 31, 2025; expects $25M milestone from Mirum in H1 2026.","Phase 3 HARMONY study of pegtibatinase in HCU resumed enrollment; primary endpoint tHcy change."],"urls":{"canonical":"https://secwatch.observer/filing/0001438533-26-000013","json":"https://secwatch.observer/filing/0001438533-26-000013.json","markdown":"https://secwatch.observer/filing/0001438533-26-000013.md","text":"https://secwatch.observer/filing/0001438533-26-000013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438533/000143853326000013/0001438533-26-000013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438533/000143853326000013/tvtx-20260219.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:42:12.119768+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}